24 PALS only. Everyone gets drug. Somewhat liberal inclusion criteria for early-middle disease.
Trial sites: E/W/S coasts in US, also Canada. Basics are here. Though this is a safety study, data in their MG safety study was encouraging in terms of efficacy signal.
The usual criteria allow riluzole and now radicava as long as you have been on a stable dose for thirty days When screening Supplements and other medications that are currently in clinical trials are not allowed within 30 days of screening.